How Analysts Feel About RedHill Biopharma Ltd. (NASDAQ:RDHL)?
Market News Eugene Fortune
The stock decreased 4.65% or $0.31 during the last trading session, reaching $6.36. About 333,748 shares traded or 27.69% up from the average. RedHill Biopharma Ltd. (NASDAQ:RDHL) has declined 24.34% since December 4, 2018 and is downtrending. It has underperformed by 24.34% the S&P500.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company has market cap of $221.69 million. The firm promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment ...